{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-051737","form_type":"8-K","ticker":"NUWE","cik":"0001506492","company_name":"Nuwellis, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.302628+00:00","generated_at":"2026-06-08T14:46:57.908662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuwellis Q3 revenue up 17% YoY to $2.4M; net loss narrows to $3.4M","bullets":["Revenue of $2.4M (+17% YoY); circuit sales driving growth with 26% increase in therapy utilization.","Gross margin 57.3% vs 61.0% YoY due to lower console volumes; disposable margins at 74.0%.","Net loss $3.4M ($1.81 loss per share) vs $3.9M ($36.72) YoY; lower expenses and higher share count.","Cash $4.9M, no debt; closed $2.25M public offering on Oct 17 for additional capital.","Collaborations with SeaStar (pediatric SCD device distribution) and DaVita (pilot phase) progressing."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-051737","json":"https://secwatch.observer/filing/0001140361-23-051737.json","markdown":"https://secwatch.observer/filing/0001140361-23-051737.md","text":"https://secwatch.observer/filing/0001140361-23-051737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123051737/0001140361-23-051737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123051737/ef20014069_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:46:57.908662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce182263da2073c472fa0551d954cbe385973df4","claim":"Nuwellis, Inc. reported the third quarter ended September 30, 2023 results: revenue $2.4 million, net income $3.4 million, EPS a loss of $1.81 per share.","evidence_excerpt":"company dedicated to transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2023. • Revenue of $2.4 million for the third quarter 2023, increased 16% over the prior quarter and increased 17% over the prior-year period. • Therapy utilization, or the number of circuits per placed","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123051737/0001140361-23-051737-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$2.4 million"},{"label":"Net income","value":"$3.4 million"},{"label":"EPS","value":"a loss of $1.81 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}